Drug Pipeline Monthly Update

Critical updates in an ever changing environment

April 2018

New drug information

- **Symfi™ (efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg):**
  Mylan received approval from the Food and Drug Administration (FDA) for Symfi, a once-daily, triple-combination complete regimen for the treatment of HIV-1 infection in adults and children weighing > 40 kg. Symfi contains the same ingredients found in the recently approved and launched Symfi Lo, but has a 600 mg dose of efavirenz versus the 400 mg in Symfi Lo. Symfi also contains the same 600 mg dose of efavirenz seen in Gilead’s Atripla. Symfi is anticipated to launch in the second quarter of 2018.¹

New generics

- **Norvir® (ritonavir) tablets:** West-Ward has launched the first generic version of AbbVie’s Norvir tablets for the treatment of HIV. West-Ward will have an 180-day period of exclusivity before multiple manufacturers can launch their generic versions of Norvir tablets. U.S. annual sales of Norvir in the past year were approximately $208.5 million, according to IMS data.

- **Safyral® (drospirenone/ethinyl estradiol/levomefolate):** Lupin launched its generic version of Bayer Healthcare Pharma’s Safyral for pregnancy prevention. According to IMS data, Safyral had approximately $22 million in U.S. sales over the past year.

- **Cyclophosphamide® (cyclophosphamide):** Amerigen launched the first generic version of West-Ward’s Cyclophosphamide capsules for malignant diseases and for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy.

- **Fazaclo® ODT (clozapine):** Teva launched the first generic for Jazz Pharmaceuticals’ Fazaclo orally disintegrating tablets (ODT) for the treatment of schizophrenia.

References


All brand names are property of their respective owners.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status.

Each trademarked drug name is the property of its respective owner.

2992-A1 © Prime Therapeutics LLC 04/18